Zacks Investment Research on MSN

GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View

GSK plc GSK reported third-quarter 2025 core earnings of $1.48 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.26. Core earnings increased 11% year over year on a ...

GSK forges pact with Empirico for respiratory siRNA in $745m deal

GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.
pharmaphorum

GSK strikes again, adding COPD candidate in $745m deal

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...
The American Journal of Managed Care

Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma

Mepolizumab significantly reduced healthcare resource utilization, including hospitalizations and emergency department visits, in patients with severe eosinophilic asthma over two years. The treatment ...